NL1025414A1 - Bereiding van gesubstitueerde chinazolinen. - Google Patents

Bereiding van gesubstitueerde chinazolinen.

Info

Publication number
NL1025414A1
NL1025414A1 NL1025414A NL1025414A NL1025414A1 NL 1025414 A1 NL1025414 A1 NL 1025414A1 NL 1025414 A NL1025414 A NL 1025414A NL 1025414 A NL1025414 A NL 1025414A NL 1025414 A1 NL1025414 A1 NL 1025414A1
Authority
NL
Netherlands
Prior art keywords
preparation
substituted quinazolines
quinazolines
substituted
Prior art date
Application number
NL1025414A
Other languages
English (en)
Other versions
NL1025414C2 (nl
Inventor
Hubert Gangolf Klemens Barth
Alexander James Bridges
Ronald Joseph Heemstra
Nicole Marcia Horne
Robert Craig Hughes
Thomas Elliott Jacks
Dennis Joseph Mcnamara
Simon Schneider
Klaus Irenous Steiner
Peter Laurence Toogood
Roy Thomas Winters
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NL1025414A1 publication Critical patent/NL1025414A1/nl
Application granted granted Critical
Publication of NL1025414C2 publication Critical patent/NL1025414C2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NL1025414A 2003-02-05 2004-02-05 Bereiding van gesubstitueerde chinazolinen. NL1025414C2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44509503P 2003-02-05 2003-02-05
US44509503 2003-02-05

Publications (2)

Publication Number Publication Date
NL1025414A1 true NL1025414A1 (nl) 2004-08-06
NL1025414C2 NL1025414C2 (nl) 2005-11-01

Family

ID=32850969

Family Applications (3)

Application Number Title Priority Date Filing Date
NL1025414A NL1025414C2 (nl) 2003-02-05 2004-02-05 Bereiding van gesubstitueerde chinazolinen.
NL1029763A NL1029763C2 (nl) 2003-02-05 2005-08-18 Bereiding van gesubstitueerde chinazolinen.
NL1029762A NL1029762C2 (nl) 2003-02-05 2005-08-18 Bereiding van gesubstitueerde chinazolinen.

Family Applications After (2)

Application Number Title Priority Date Filing Date
NL1029763A NL1029763C2 (nl) 2003-02-05 2005-08-18 Bereiding van gesubstitueerde chinazolinen.
NL1029762A NL1029762C2 (nl) 2003-02-05 2005-08-18 Bereiding van gesubstitueerde chinazolinen.

Country Status (18)

Country Link
US (1) US20040158065A1 (nl)
EP (1) EP1618095A2 (nl)
JP (1) JP2006517959A (nl)
KR (1) KR20050095916A (nl)
CN (1) CN1745073A (nl)
AR (1) AR043027A1 (nl)
AU (1) AU2004209452A1 (nl)
BR (1) BRPI0407249A (nl)
CA (1) CA2514933A1 (nl)
MX (1) MXPA05007831A (nl)
NL (3) NL1025414C2 (nl)
PA (1) PA8595201A1 (nl)
PE (1) PE20040945A1 (nl)
PL (1) PL378576A1 (nl)
RU (1) RU2005122322A (nl)
TW (1) TW200420544A (nl)
UY (1) UY28177A1 (nl)
WO (1) WO2004069791A2 (nl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA71976C2 (en) * 1999-06-21 2005-01-17 Boehringer Ingelheim Pharma Bicyclic heterocycles and a medicament based thereon
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
US7452895B2 (en) * 2003-08-14 2008-11-18 Array Biopharma Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
US7501427B2 (en) * 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
DE10349113A1 (de) * 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
UA85706C2 (en) * 2004-05-06 2009-02-25 Уорнер-Ламберт Компани Ллси 4-phenylaminoquinazolin-6-yl amides
KR100735639B1 (ko) * 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
KR100832594B1 (ko) * 2005-11-08 2008-05-27 한미약품 주식회사 다중저해제로서의 퀴나졸린 유도체 및 이의 제조방법
EP3173084B1 (en) 2005-11-11 2019-10-23 Boehringer Ingelheim International GmbH Quinazoline derivatives for the treatment of cancer diseases
ZA200804498B (en) 2005-11-15 2009-07-29 Array Biopharma Inc N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ERBB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
ES2385613T3 (es) * 2006-09-18 2012-07-27 Boehringer Ingelheim International Gmbh Método para tratar cánceres que portan mutaciones de EGFR
WO2009035718A1 (en) * 2007-09-10 2009-03-19 Curis, Inc. Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety
EP2242493B1 (en) * 2008-01-22 2013-06-05 Concert Pharmaceuticals Inc. Derivatives of gefitinib
WO2009094210A1 (en) * 2008-01-22 2009-07-30 Concert Pharmaceuticals Inc. Vandetanib derivatives
NZ621143A (en) * 2008-09-05 2016-08-26 Celgene Avilomics Res Inc Algorithm for designing irreversible inhibitors
US9545381B2 (en) 2009-07-06 2017-01-17 Boehringer Ingelheim International Gmbh Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
IN2012DN02534A (nl) 2009-09-16 2015-08-28 Avila Therapeutics Inc
AU2010339456A1 (en) 2009-12-30 2012-07-05 Celgene Avilomics Research, Inc. Ligand-directed covalent modification of protein
CN102382106A (zh) 2010-08-30 2012-03-21 黄振华 苯胺取代的喹唑啉衍生物
WO2013013640A1 (zh) * 2011-07-27 2013-01-31 上海医药集团股份有限公司 喹唑啉衍生物、其制备方法、中间体、组合物及其应用
JP2014532063A (ja) * 2011-10-12 2014-12-04 テリジェン リミテッドＴｅｌｉｇｅｎｅ Ｌｔｄ キナーゼ阻害剤としてのキナゾリン誘導体およびその使用方法
US9388170B2 (en) 2012-05-07 2016-07-12 Teligene Ltd. Substituted aminoquinazolines useful as kinases inhibitors
CN103965120B (zh) * 2013-01-25 2016-08-17 上海医药集团股份有限公司 喹啉及喹唑啉衍生物、制备方法、中间体、组合物及应用
CN103242244B (zh) * 2013-05-16 2015-03-25 苏州明锐医药科技有限公司 一种卡奈替尼的制备方法
JP6139782B2 (ja) 2013-05-21 2017-05-31 チャンスー メドリューション リミテッド 置換ピラゾロピリミジン化合物、及びその薬学的に許容される塩、並びにこれらの溶媒和物、立体異性体、及び互変異性体、並びにこれらを含む医薬組成物
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
US10870627B2 (en) 2016-09-23 2020-12-22 Shanghai Pharmaceuticals Holding Co., Ltd. Salt of quinazoline derivative, preparation method therefor and application thereof
SI3762368T1 (sl) 2018-03-08 2022-06-30 Incyte Corporation Aminopirazin diolne spojine kot zaviralci PI3K-y
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
CN113382986A (zh) 2018-09-25 2021-09-10 黑钻治疗公司 酪氨酸激酶抑制剂组合物、其制备方法和使用方法
SG11202108752YA (en) * 2019-03-07 2021-09-29 BioNTech SE Process for the preparation of a substituted imidazoquinoline
KR20220147021A (ko) * 2021-04-22 2022-11-02 보로노이 주식회사 헤테로아릴 유도체 화합물 및 이의 용도
WO2023044364A1 (en) 2021-09-15 2023-03-23 Enko Chem, Inc. Protoporphyrinogen oxidase inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126351A0 (en) * 1996-04-12 1999-05-09 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
US6664390B2 (en) * 2000-02-02 2003-12-16 Warner-Lambert Company Llc Method for the simplified production of (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-nitro-quinazoline-4-yl]-amine or (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-amino-quinazoline-4-yl]-amine
DE10009267A1 (de) * 2000-02-26 2001-08-30 Goedecke Ag Verfahren zur einfachen Herstellung von (3-Chlor-4-fluor-phenyl)-[7-(3-morpholin-4-yl-propoxy)-6-nitro-quinazolin-4-yl]-amin bzw. (3-Chlor-4-fluor-phenyl)-[7-(3-morpholin-4-yl-propoxy)-6-amino-quinazolin-4-yl]-amin
US6627634B2 (en) * 2000-04-08 2003-09-30 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
DE10063435A1 (de) * 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
CN1745073A (zh) 2006-03-08
UY28177A1 (es) 2004-09-30
KR20050095916A (ko) 2005-10-04
NL1025414C2 (nl) 2005-11-01
JP2006517959A (ja) 2006-08-03
TW200420544A (en) 2004-10-16
US20040158065A1 (en) 2004-08-12
AU2004209452A1 (en) 2004-08-19
WO2004069791A2 (en) 2004-08-19
NL1029762C2 (nl) 2006-03-06
PA8595201A1 (es) 2004-09-16
EP1618095A2 (en) 2006-01-25
RU2005122322A (ru) 2006-03-10
BRPI0407249A (pt) 2006-01-31
AR043027A1 (es) 2005-07-13
PL378576A1 (pl) 2006-05-02
PE20040945A1 (es) 2004-12-14
MXPA05007831A (es) 2005-10-18
NL1029762A1 (nl) 2005-10-13
WO2004069791A3 (en) 2004-12-16
NL1029763A1 (nl) 2005-10-13
NL1029763C2 (nl) 2006-03-06
CA2514933A1 (en) 2004-08-19

Similar Documents

Publication Publication Date Title
NL1029762A1 (nl) Bereiding van gesubstitueerde chinazolinen.
DK1667992T3 (da) Quinazolinderivater
DE602004007458D1 (de) Symmetrierglied
DE602004022180D1 (de) Chinazolinderivate
DE602004007220D1 (de) Verbinder
DE602004031798D1 (de) Verbinder
DK1474420T3 (da) Quinazolinforbindelser
MX266708B (es) Formulaciones de microparticulas de pantoprazol.
DE602004022898D1 (de) Verbinder
DE502004011106D1 (de) 6-arylmethyl-substituierte pyrazolopyrimidine
DE60311073D1 (de) Belüftungseinrichtung
DE602004026397D1 (de) Verbinder
ATE366242T1 (de) 5-substituierte chinazolinonderivate
DK1636288T3 (da) Tværbindende vandige polyurethandispersioner
DE502004003715D1 (de) Selbstsperrender gurtaufroller
DE502004003432D1 (de) Antennenkoppler
ATE444953T1 (de) Substituierte spirobenzazepine
DE502004001587D1 (de) Arretierelement
DE602004003978D1 (de) Verbinder
DE502004009935D1 (de) Substituierte dihydrochinazoline ii
DE60322439D1 (de) Anschlussstück
DE60316553D1 (de) Verbinder
DE602004009500D1 (de) Verbinder
DE602004029309D1 (de) Verbinder
DE602004000496D1 (de) Verbinder

Legal Events

Date Code Title Description
AD1A A request for search or an international type search has been filed
RD2N Patents in respect of which a decision has been taken or a report has been made (novelty report)

Effective date: 20050628

PD2B A search report has been drawn up
VD1 Lapsed due to non-payment of the annual fee

Effective date: 20080901